Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd. is a biopharmaceutical company primarily focused on developing innovative treatments for life-threatening immune system disorders. The core of its research centers around its proprietary Allocetra technology, designed to reprogram the host immune system to resolve severe inflammations without suppressing it entirely. This approach is aimed at addressing a range of critical conditions such as sepsis, a leading cause of death in intensive care units, and other inflammatory diseases. Enlivex Therapeutics is significantly involved in the healthcare sector, directly impacting the biopharmaceutical industry with its novel treatment modalities. Headquartered in Ness Ziona, Israel, the company plays a pivotal role in the biotechnology landscape by potentially transforming the way immune-related disorders are treated globally. Its commitment to advancing medical science highlights its importance in addressing unmet medical needs and enhancing patient outcomes.